Meeting
2020 Gastrointestinal Cancers Symposium
Circulating IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer.
Authors
Mitsukuni Suenaga
Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Mitsukuni Suenaga , Tetsuo Mashima , Naomi Kawata , Takeru Wakatsuki , Hiroyuki Seimiya , Kensei Yamaguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 172)
Abstract #
172
Poster Bd #
H14
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR).
First Author: Yoshiyuki Yamamoto
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer using a multi-marker panel and a machine-learning approach: Final results of the prospective multicenter PERMAD trial.
First Author: Hans A. Kestler
Poster
2016 Gastrointestinal Cancers Symposium
Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC).
First Author: Michael Teufel
Poster
2014 Gastrointestinal Cancers Symposium
Il-8 as an underutilized prognostic factor in metastatic colorectal cancer.
First Author: Manasi S Shah